Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Huebsch, Nathaniel ^a,b   Loskill, Peter ^c,d   Deveshwar, Nikhil ^c   Spencer, C Ian ^a   Judge, Luke M ^a,b   Mandegar, Mohammad A ^a   Fox, Cade B ^e   Mohamed, Tamer M A ^a,f,g   Ma, Zhen ^c,d   Mathur, Anurag ^c,d   Sheehan, Alice M ^a   Truong, Annie ^a   Saxton, Mike ^a   Yoo, Jennie ^a   Srivastava, Deepak ^a,b   Desai, Tejal A ^e   So, Po Lin ^a   Healy, Kevin E ^c,d   Conklin, Bruce R ^a,e  

^a GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

^d University of California Berkeley   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g Zagazig University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC MUSCLE CELL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; INDUCED PLURIPOTENT STEM CELL; PHYSIOLOGY; SARCOMERE; STROMA CELL;

CELL DIFFERENTIATION; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; SARCOMERES; STROMAL CELLS;

EID: 84964461990     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24726     Document Type: Article

References (39)

1. Mathur, A. et al. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem cell research & therapy. 4 Suppl 1, S14 (2013).
2. Bian, W. et al. N. Robust T-tubulation and maturation of cardiomyocytes using tissue-engineered epicardial mimetics. Biomaterials. 35(12), 3819-28 (2014).
3. Hirt, M. N. et al. Increased afterload induces pathologic cardiac hypertrophy: a new in vitro model. Basic Res Cardiol. 107(6), 307 (2012).
4. Nunes, S. S. et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 10(8), 781-7 (2013).
5. Mathur, A. et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci. Rep. 5, 8883 (2015).
6. Tiburcy, M. et al. Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ Res. 109, 1105-1114 (2011).
7. Zimmermann, W. H. et al. Tissue engineering of a differentiated cardiac muscle construct. Circ Res. 90(2), 223-30 (2002).
8. Stoehr, A. et al. Automated analysis of contractile force and Ca2+ transients in engineered heart tissue. Am J Physiol Heart Circ Physiol. 306, H1353-63 (2014).
9. Hansen, A. et al. Development of a drug screening platform based on engineered heart tissue. Circ Res. 107(1), 35-44 (2010).
10. Tulloch, N. L. et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res. 109(1), 47-59 (2011).
11. Thavandiran, N. et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc. Natl. Acad. Sci. USA 110(49), E4698-707 (2013).
12. Miyaoka, Y. et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods. 11(3), 291-3 (2014).
13. Vollert, I. et al. In Vitro Perfusion of Engineered Heart Tissue Through Endothelialized Channels. Tissue Eng. Part A. 20(3-4), 854-63 (2014).
14. Legant, W. R. et al. Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues. Proc. Natl. Acad. Sci. USA 106(25), 10097-102 (2009).
15. Boudou, T. et al. A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues. Tissue Eng. Part A. 18(9-10), 910-9 (2012).
16. Feinberg, A. W. et al. Functional differences in engineered myocardium from embryonic stem cell-derived versus neonatal cardiomyocytes. Stem Cell Reports. 1(5), 387-96 (2013).
17. Ribeiro, A. J. et al. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physyiological shape and substrate stiffness. Proc. Natl. Acad. Sci. USA 112(41), 12705-10 (2015).
18. Tiburcy, M., Zimmermann, W. H. Modeling myocardial growth and hypertrophy in engineered heart muscle. Trends Cardiovasc Med. 24(1), 7-13 (2014).
19. Desroches, B. R. et al. Functional scaffold-free-3-D cardiac microtissues: a novel model for the investigation of heart cells. Am J Physiol Heart Circ Physiol. 302, H2031-42 (2012).
20. Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proceedings Of The National Academy Of Sciences Of The United States Of America. 109, E1848-1857 (2012).
21. Toyhama, S. et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 12(1), 127-37 (2013).
22. Hockemeyer, D. et al. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell. 3(3), 346-53 (2008).
23. Zhang, D. et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials. 34, 5813-20 (2013).
24. Huebsch, N., Loskill, P. et al. Automated video-based analysis of contractility and calcium flux in human-induced pluripotent stemderived cardiomyocytes cultured over different spatial scales. Tissue Eng. Part C. Methods. 21(5), 467-79 (2015).
25. Camelliti, P., Borg, T. K., Kohl, P. Structural and functional characterization of cardiac fibroblasts. Cardiovasc Res. 65(1), 40-51 (2005).
26. Nguyen, D. C. et al. Microscale generation of cardiospheres promotes robust enrichment of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Reports. 3(2), 260-8 (2014).
27. Oyer, J. A. et al. Aberrant Epigentic Silencing Is Triggered by a Transient Reduction in Gene Expression. PLos One. 4(3), e4832 (2009).
28. Chen, T. W. et al. Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature 499(7458), 295-300 (2013).
29. Brown, M. J., Brown, D. C., Murphy, M. B. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. New Eng. J. Med. 309, 1414-9 (1983).
30. Navarrete, E. G. et al. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation. 129(15), e452 (2013).
31. Yang, X., Pabon, L., Murry, C. E. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyoctyes. Circ. Res. 114(3), 511-23 (2014).
32. Wu, H. et al. Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised ?-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. Cell Stem Cell. 17(1), 89-100 (2015).
33. Gorder-Furnemont, A. F. et al. Physiologic force-frequency response in engineered heart muscle by electromechanical stimulation. Biomaterials. 60, 82-91 (2015).
34. Yang, X. et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 72, 296-304 (2014).
35. Lundy, S. D. et al. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 22(14), 1991-2002 (2013).
36. Ribeiro, M. C. et al. Functional maturation of human pluripotent stem cell derived cardiomyocytes in vitro-corelation between contraction force and electrophysiology. Biomaterials. 51, 138-50 (2015).
37. Ruan, J. L. et al. Mechanical Stress Promotes Maturation of Human Myocardium from Pluripotent Stem Cell-Derived Progenitors. Stem Cells. 33(7), 2148-57 (2015).
38. Kirkton, R. D., Bursac, N. Engineering biosynthetic excitable tissues from unexcitable cells for electrophysiological and cell therapy studies. Nat. Commun. 2, 300 (2011).
39. Schaefer, J. A., Tranquillo, R. T. Tissue Contraction Force Microscopy for Optimization of Engineered Cardiac Tissue. Tissue Eng Part C Methods. 22(1), 76-83 (2016).